Literature DB >> 9989719

Risk of new AIDS diseases in people on triple therapy.

V Miller, S Staszewski, G Nisius, A C Lepri, C Sabin, A N Phillips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9989719     DOI： 10.1016/S0140-6736(98)04954-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier.

Authors:  Marianne Strazza; Vanessa Pirrone; Brian Wigdahl; Michael R Nonnemacher
Journal:  Brain Res       Date:  2011-05-14       Impact factor: 3.252

3.  The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.

Authors:  Alana T Brennan; Mhairi Maskew; Ian Sanne; Matthew P Fox
Journal:  Trop Med Int Health       Date:  2013-02-18       Impact factor: 2.622

4.  CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

Authors:  H J Zambarakji; R B Newson; S M Mitchell
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

5.  Continuing HIV therapy in the ICU.

Authors:  N Soni; A Pozniak
Journal:  Crit Care       Date:  2001-09-13       Impact factor: 9.097
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.